Prediction of active ingredients and potential mechanisms of Alisma decoction against atherosclerosis:A study based on UHPLC-Q-Orbitrap-HRMS and network pharmacology

Background:Atherosclerosis(AS)has been a potentially life-threatening disease worldwide.Alisma decoction(AD)is a famous Chinese formula in treating AS.However,the active components and potential mechanisms remain unknown.Methods:In this study,the active compositions of AD were analyzed by ultrahigh-performance liquid chromatography quadrupole-orbitrap high-resolution mass spectrometry(UHPLC-Q-Orbitrap-HRMS).The putative targets were predicted and interpreted by a series of bio-informative tools such as Venn,STRING,NetworkAnalyzer,ClusterMarker,and DAVID.Finally,the results were validated by molecular docking using AutoDock.Results:The results showed that alisol A,alisol B,23-o-Acetylalisol B,atractylenolideⅢand atractylenolideⅡwere the major compositions in AD.Thirty targets mainly distributed in three gene clusters were obtained after topological and cluster analysis.KEGG and GO analyses showed that genes in cluster 1 mainly participated in adipocytokine signaling pathway and played an important role in lipid metabolism,while genes in cluster 2 had regulatory actions via cAMP signaling pathway and may protect vascular function from AS,and genes in cluster 3 were closely related to inflammation.Furthermore,RXRA,AGT and CXCL8,the central gene of cluster 1,2 and 3,were verified to be strong binding with some major compositions in AD.Conclusion:The possible mechanisms of AD in the treatment of AS may be closely correlated with the regulation of lipid metabolism,vascular physiology and inflammation.Our study provided a new insight into the anti-AS effect of AD,but more pharmacological experiments should be performed for verification in the future.

Discussion on Maxing Ganshi Decoction in the Treatment of COVID-19 Based on Triple Energizer Transmission Theory

COVID-19 is caused by novel coronavirus(2019-nCoV),which has the characteristics of strong infectivity,rapid onset and rapid spread.It is popular in China and other parts of the world,and there are no special drugs at present.This disease belongs to the category of plague in traditional Chinese medicine.Combined with the theory of triple energizer transmission in Yang Lishan's"Identification of Warm Disease",the confirmed case in our hospital was analyzed,and it was found that pathogenic qi entered from nose and mouth,injected into middle energizer,and then distributed in upper and lower energizer.The pathogenic qi is mainly diffused in the middle and upper energizer.Modified Maxing Ganshi decoction has a good effect.

Clinical efficacy of integrated Chinese and western medicine in the treatment of the corona virus disease 2019(COVID-19):A meta-analysis

Objective:To evaluate the clinical efficacy of integrated Chinese and western medicine(ICWM)in the treatment of COVID-19.Methods:Literature retrieval was performed in PubMed,Cochrane Library,EMBASE,Web of science,CNKI,VIP and Wanfang database from inception to November 1,2020.The data extraction and quality assessment were completed by two independent reviewers.Meta-analysis was performed using Review Manager 5.3.Results:30 clinical trials were included with 3379 participants.The meta-analysis showed that there were significant differences in the total effective rate(RR=1.24,95%CI[1.15,1.35];P<0.01),the conversion rate from mild or moderate to severe(RR=0.32,95%CI[0.24,0.44];P<0.01),the mortality(RR=0.52,95%CI[0.30,0.93];P<0.05),the disappearance time of fever(MD=-1.60,95%CI[-1.99,-1.21];P<0.01)and cough(MD=-1.43,95%CI[-1.96,-0.90];P<0.01)and fatigue(MD=-1.44,95%CI[-2.33,-0.55];P<0.01),the rate of CT improvement(RR=1.29,95%CI[1.13,1.47];P<0.01)and the rate of adverse reactions(RR=0.52,95%CI[0.31,0.87];P<0.05)between ICWM and western medicine(WM)alone.While there were no differences between two groups in the cure rate(RR=1.22,95%CI[0.98,1.52];P>0.05)and the disappearance rate of fatigue(RR=1.18,95%CI[0.97,1.45];P>0.05).Conclusion:Meta-analysis results indicated that ICWM in the treatment of COVID-19 can improve clinical efficacy and safety.However,high-quality,large-sample,multi-center RCTs are required to confirm the efficacy of traditional Chinese medicine intervention COVID-19.

Research progress of traditional Chinese medicine in the treatment of breast cancer based on “Binding of Phlegm and Stasis”

Breast cancer is a common malignancy in female,which seriously endangers women’s health.Chinese medicine believed that the incidence of breast cancer is related to“Stagnation of Liver-Qi”and“Phlegm,Disharmony of Thoroughfare and Conception Vessels”,“Stagnation of Qi and Blood Stasis”,constitution and other characteristics.Modern research believed that phlegm is related to abnormal energy metabolism of tumor cells,and stasis is the pathological change of tumor angiogenesis.How to combine tumor angiogenesis and energy replacement abnormality with the theory of“Binding of Phlegm and Stasis”has become a new direction of traditional Chinese medicine anti-tumor research.The drugs of“Activating Blood Circulation”and“Removing Blood Stasis”,“Resolving Phlegm”and“Dispersing Constipation”have a wide range of pharmacological effects and definite curative effect.They have the functions of anti-inflammatory,anti-tumor,anti-pathogenic microorganism and improving the immune ability of the body.In this paper,the effects and mechanisms of phlegm-reducing and stasis dispersing active ingredients and compound preparations in regulating angiogenesis and energy metabolism of breast cancer were reviewed,and the differences in efficacy,targets and pathways of Phlegm-Reducing and Stasis Dispersing drugs were summarized,so as to provide some reference for the research and development of traditional Chinese medicine for breast cancer.